Latest Blogs

Jun 20, 2017
New immunotherapies are offering astounding responses, but my patient's remission came at the cost of debilitating toxicity. How much is too much to bear?
Jun 13, 2017
"Reflection kept bringing me back to a simple truth: my job as a mother and my job as a physician are strikingly similar," writes Dr. Stephanie Graff.
Jun 13, 2017
Dr. McAneny's broad expertise and insight on today’s challenging health care environment will greatly benefit the practice of medicine and our patients.
Jun 12, 2017
Preparing for the future starts with gaining clarity about the present state of oncology care. Our goal is for practices in all settings across the U.S. to provide feedback in the 2017 ASCO Practice Census.
Subscribe to this column

Gilberto Lopes, MD, MBA

Gilberto de Lima Lopes Jr., MD, MBA, FAMS, a medical oncologist, is medical director for international programs and associate director for global oncology at the Sylvester Comprehensive Cancer Center and associate professor of clinical medicine at the University of Miami in Florida. He returned to the United States after 10 years in Asia and Latin America and has dedicated much of his time to the issues of cancer control and access to medications in low- and middle-income countries. Dr. Lopes is the editor in chief of ASCO's Journal of Global Oncology, associate editor for the ASCO University Editorial Board, 2016-2017 chair of the International Clinical Trials Workshop Working Group, and global health track leader for the Cancer Education Committee, among other volunteer roles. Follow him on Twitter @GlopesMd.

Mar 20, 2017
When the basics of cancer control are not in place, should we discuss targeted agents and immunotherapy in resource-constrained settings?
Oct 31, 2016
Hope springs eternal in the Brazilian economy and health care system, with cautious optimism for gains in oncology care.
Oct 04, 2016
Inequalities, especially in health care, breed discontent. We need better ways to continue incentivizing the development of new drugs while optimizing access. Biosimilars help, but they won't solve the whole problem.
Aug 01, 2016
The region has seen structural reforms in health care systems, better training of cancer professionals, new initiatives for populations at high risk, expansion of cancer registries and cancer plans, and implementation of policies to improve prevention, early diagnosis, and treatment.
Jul 11, 2016
Follow-on biologics are here to stay, and represent enormous potential for patients with cancer being treated in low- and middle-income countries.
May 23, 2016
This is the story of how, like Mr. Smith in Washington, the medical community in Brazil gathered to speak truth to power about the lack of evidence for phosphoethanolamine as a cancer treatment.

Pages